GU Cancers 2023 | Avelumab plus axitinib shows good efficacy for OS and PFS in aRCC patients

Anand Sharma, MD, D.Phil, MRCP, MBBS, Mount Vernon Cancer Centre, East and North Hertfordshire NHS Trust, Northwood, UK, provides promising updates on a study (NCT05394493) of avelumab plus axitinib to treat advanced renal cell carcinoma (aRCC) in the first-line setting. The study reported good efficacy after 24 months for overall survival (OS) and progression-free survival (PFS) for patients with favorable, intermediate, and poor risk aRCC. This interview took place at the American Clinical Society of Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.